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Abstract
Background—Obesity and obstructive sleep apnea syndrome (OSA) are highly prevalent and 
frequently overlapping conditions in children that lead to systemic inflammation, the latter being 
implicated in the various end-organ morbidities associated with these conditions.
Aim—To examine the effects of adenotonsillectomy (T&A) on plasma levels of inflammatory 
markers in obese children with polysomnographically diagnosed OSA who were prospectively 
recruited from the community.
Methods—Obese children prospectively diagnosed with OSA, underwent T&A and a second 
overnight polysomnogram (PSG) after surgery. Plasma fasting morning samples obtained after 
each of the 2 PSG were assayed for multiple inflammatory and metabolic markers including 
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interleukin-6 (IL-6), IL-18, plasminogen activator inhibitor-1 (PAI-1), monocyte chemoattractant 
protein-1 (MCP-1), matrix metalloproteinase- (MMP-9), adiponectin, apelin C, leptin and 
osteocrin.
Results—Out of 122 potential candidates, 100 obese children with OSA completed the study 
with only 1/3 exhibiting normalization of their PSG after T&A (i.e., AHI≤1/hrTST). However, 
overall significant decreases in MCP-1, PAI-1, MMP-9, IL-18 and IL-6, and increases in adropin 
and osteocrin plasma concentrations occurred after T&A. Several of the T&A responsive 
biomarkers exhibited excellent sensitivity and moderate specificity to predict residual OSA (i.e., 
AHI≥/hrTST).
Conclusions—A defined subset of systemic inflammatory and metabolic biomarkers is 
reversibly altered in the context of OSA among community-based obese children, further 
reinforcing the concept on the interactive pro-inflammatory effects of sleep disorders such as OSA 
and obesity contributing to downstream end-organ morbidities.
Keywords
sleep apnea; children; obesity; inflammation; cytokines; biomarkers
Introduction
Obstructive Sleep Apnea (OSA) is a very frequent condition in obese children that has been 
associated with a heightened risk for end-organ morbidities affecting the central nervous 
system (CNS), as well as promoting the emergence of cardiovascular and metabolic deficits 
in the context of pediatric obesity (1). The mechanisms underlying the increased risk for 
adverse consequences in obese children with OSA have been putatively ascribed to 
activation of systemic inflammatory pathways (2-5). Indeed, increased plasma levels of 
inflammatory mediators, such as high–sensitivity C-reactive protein, tumor necrosis factor 
α, IL-6 and interferon γ have been repeatedly documented (6,7). However, most of the 
published studies have relied on either the cross-sectional exploration of potential 
associations between sleep perturbations that characterize OSA and inflammatory markers, 
or alternatively have explored the effect of adenotonsillectomy (T&A) in clinical referral 
cohorts rather than community-based populations (2,8,9).
In the present study, we hypothesized that a cluster of inflammatory biomarkers previously 
identified as being affected by pediatric OSA (10, 11) may be responsive to treatment and 
enable identification of obese children with residual OSA after T&A. To this effect, we took 
advantage of a multicenter prospective pediatric clinical trial (12), to investigate the effect of 
T&A on several plasma inflammatory biomarkers in obese children from the community 
who were prospectively diagnosed with OSA and underwent surgical removal of enlarged 
tonsils and adenoids.
Subjects and Methods
124 obese children (ages 4-15 years) who were initially recruited from the community 
through their general pediatrician offices and were polysomnographically diagnosed with 
OSA (44 from Spain and 80 from Chicago) were referred for T&A, and invited to return for 
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a follow-up PSG and morning fasting blood draw within 6 months of their surgical 
intervention. The study was approved by the human subject committee of each of the 
participating centers (University of Chicago IRB Protocol #: 10-708-A-AM017 and Comité 
Ético de Investigación Clínica del Área de Salud de Burgos y Soria protocol number 603), 
and is in accordance with the STROBE statement. The study was registered at 
ClinicalTrials.gov under NCT01322763. Informed consent was obtained from each legal 
caretaker, and assent was obtained from children if they were 12 years old or older. Data 
were coded to mask the identity, and any other personal information for all the subjects, 
thereby ensuring confidentiality. Samples and de-identified data from Spanish subjects 
included in this study were provided by the Basque Biobank for research OEHUN 
(www.biobancovasco.org), and were processed following standard operating procedures 
with appropriate approvals from the Ethical and Scientific Committees.
Anthropometric Measures and Overnight Polysomnography (PSG)
In the evening of the PSG tsting, assessments of height in meters, weight in kilograms, and 
BMI z score were performed. In addition, neck circumference was measured at the level of 
the cricopharyngeal membrane, and both waist and abdominal circumferences were 
measured with a measuring tape. Obesity was defined as a BMI >95% for age and gender (5, 
12). PSG tests were conducted in a sleep laboratory under standardized conditions both 
during the initial phase aiming at determining the presence of OSA and within 6 months 
after T&A to assess the outcomes of the surgical procedure. The studies were scored, after 
removal of movement and technical artifacts, according to the standard criteria defined by 
the American Academy of Sleep Medicine (AASM) (13). Briefly, obstructive sleep apnea 
was defined as cessation of airflow with continued chest wall and abdominal movements for 
the duration of at least of two breaths. Hypopnea was defined as a decrease in nasal flow 
greater than 50%, corresponding to at least 4% decrease in the oxygen saturation (SpO2) as 
measured by pulse oximetry and/or terminated by a 3-second EEG arousal (14). The 
obstructive Respiratory Disturbance Index (oRDI) was calculated from the number of 
respiratory-effort related arousals and the number of apneas and hypopneas per hour of TST. 
To accommodate all the studies from both cohorts, both an apnea-hypopnea index (AHI)≥5/
hrTST and a oRDI ≥3/hr of TST were considered to indicate the presence of OSA either in 
the initial PSG or after T&A (residual OSA) in accordance with the clinical practice 
guidelines in Spain and the USA (1, 15). In addition, we also assessed for the presence of 
AHI>1/hrTST as evidence of residual OSA after T&A (1). Furthermore, nadir and mean 
SpO2, as well total sleep time during which SpO2 below 90% or end-tidal CO2> 50 mmHg 
occurred, were recorded. Oxygen desaturation index (ODI) was defined as the number of 
desaturation events ≥ 4% per hour of TST.
Inflammatory Mediator Assays
Plasma was separated from the whole blood morning samples drawn from each child and 
stored in -80°C until assay. Commercially available ELISA kits specific for each cytokine 
were used to measure levels of interleukin (IL) -6, IL-18, monocyte chemoattractant protein 
(MCP)-1, adiponectin, matrix metalloproteinase (MMP)-9, apelin C, leptin (all individual 
kits from RayBiotech, Inc., Norcross, GA, USA), adropin (Peninsula laboratories LLC, San 
Carlos, CA, USA), osteocrin (MyBioSource, San Diego, CA, USA), and plasminogen 
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activator inhibitor (PAI)-1 (Assaypro LLC, St. Charles, MO, USA). Assays were performed 
according to manufacturers’ recommendations.
Statistical analysis
Descriptive data for continuous variables are presented as means ± standard deviation (SD) 
and for categorical variables as percentages or ratios. The normal distribution of the data 
was ascertained with the Kolmogorov-Smirnov test, and natural logarithmic transformations 
were applied to linearize the data as needed. Analyses for comparisons between clinical and 
laboratory values in pre- and post T&A conditions were performed using paired Student’s t-
tests. Group comparisons were conducted using one-way ANOVA followed by Bonferroni 
correction for multiple comparisons. Pearson’s correlation was used to compare between the 
marker levels and clinical parameters. Multivariate linear regression analysis was applied to 
assess relationships of significantly different markers between the pre- and post-treatment 
conditions. In addition, receiver operator curves were constructed for individual changes in 
each of the significantly modified plasma biomarkers after T&A using previously published 
approaches (16). Simply, a cut-off criterion was initially identified using ROC analyses for 
each of the bioassay analytes, and then each individual subject was scrutinized as to whether 
they fulfilled the cut-off values for 1, 2, 3, etc… of the analytes. Then, a ROC analysis for 
those fulfilling 1, 2, >2 cut-offs of the previously identified significantly predictive analytes 
was performed to determine the predictive performance of the combinatorial approach using 
MedCalc software (http://download.cnet.com/MedCalc/3000-2053_4-10079096.html). 
Statistical significance was assumed at two-tailed p<0.05. Statistical analyses were 
performed using SPSS software (version 21.0; SPPS Inc., Chicago, Ill.).
Results
Demographic data
Of the 124 obese children from the community (ages 4-15 years) who were initially 
diagnosed with OSA and treated with surgical adenotonsillectomy,100 children completed 
their follow-up PSG and blood sample, and their demographic characteristics are described 
in Table 1. Of note, 23 of 44 initially evaluated children originated from Spain and the 77 
from the 80 children with OSA were from Chicago. The time elapsed between surgical T&A 
and the repeat PSG was 184.4 ± 23.7 days (range: 147-253 days). There were no significant 
differences between those who completed the study and those who did not, as far as their 
demographic or PSG characteristics (Tables 1 and 2). The major reasons for non-completion 
were repeated no-shows to scheduled appointments (n=17), lack of willingness to return for 
a PSG (n=6) or inability to contact the family (n=1).
Sleep Studies
PSG findings before and following T&A are summarized in Table 2. As would be 
anticipated from the literature, significant improvements in respiratory measures during 
sleep emerged after T&A (Table 2). There were no significant differences in either the total 
duration of sleep and total time in bed (Table 2). However, a substantial proportion of 
children had post-operative AHI>1/hrTST (67.0%), AHI>5/hrTST (30.0%), or RDI>3/
hrTST (40.0%), indicative of the presence of residual OSA. There were no differences 
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however in either demographic, anthropometric or polysomnographic measures among the 
obese children with OSA who normalized their PSG findings and those who did not, 
including weight gain or BMI z score changes after T&A.
Plasma Inflammatory Mediators in Obese Children with OSA before and after T&A
As shown in Table 3, among the inflammatory markers included in the present study, 
several markers were significantly improved after T&A, namely IL-6 (p<0.0001), IL-18 
(p<0.005), PAI-1 (p<0.0001), MCP-1 (p<0.003), MMP-9 (p<0.0001), and adropin 
(p<0.0001). However, no significant changes emerged in leptin and adiponectin levels for 
the whole cohort. No differences in inflammatory marker levels emerged between boys and 
girls regarding the effects of T&A. Furthermore, no significant associations emerged 
between the changes in lnAHI and lnoRDI and corresponding pre-post T&A changes in 
plasma biomarkers. However, the clinically-relevant outcome of T&A, i.e., AHI≥5/hrTST 
vs. AHI<5/hrTST, revealed major differences in several inflammatory markers that 
essentially further reinforced the changes previously found in the whole cohort (Table 4). 
Indeed, in addition to significant improvements in IL-6, IL-18, PAI-1, MCP-1, MMP-9, and 
adropin, statistically significant increases in plasma adiponectin concentrations and 
reductions in leptin levels occurred in those children with post-T&A AHI<5/hrTST (Table 
4). In contrast, for the 30% of the cohort whose post-operative AHI remained ≥5/hrTST, no 
significant changes emerged for all biomarkers except for leptin levels, which increased, 
rather than decreased (Table 4).
Based on these findings we examined receiver operator curves for prediction of T&A 
outcomes (resolved vs. persistent residual OSA using AHI≥5hrTST) initially using single 
biomarkers, and then clusters of biomarker subsets (Figure 1). Of all the biomarkers, the best 
performers included MCP-1, MMP-9, PAI-1, and adiponectin. MMP-9 and MCP-1 were 
essentially interchangeable, such that including them in combinatorial analyses did not yield 
any improvements in the AUC. Accordingly, MCP-1 and PAI-1 achieved an AUC of 0.809 
with a sensitivity of 0.7 and a specificity of 0.9 (p<0.0001; Figure 1). Addition of 
adiponectin to these 2 markers resulted in improved AUC (0.858; p<0.0001) with higher 
sensitivity (0.9) but lower specificity (0.63).
Discussion
One of the major findings of the present study is that OSA in obese children amplifies the 
underlying systemic inflammatory pathways that are a priori activated by obesity alone, as 
demonstrated by the changes in some of these inflammatory markers following effective 
resolution of OSA after T&A. Furthermore, we show that effective treatment of OSA, as 
evidenced by normalization of respiratory disturbances during sleep, is associated with 
prominent improvements in a subset of systemic inflammatory markers, particularly when 
compared to children in whom T&A resulted in less severe, yet clinically significant 
residual OSA at follow-up (i.e., AHI≥5/hrTST). Additionally, our data reinforce the concept 
that although improvements in the magnitude of respiratory disturbance occur after T&A in 
obese children with OSA, a very high risk remains that there will be incomplete resolution 
of sleep disordered breathing in this population, ranging from 30% to 67%, and depending 
Kheirandish-Gozal et al. Page 5
Int J Obes (Lond). Author manuscript; available in PMC 2016 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
on the PSG-based cut-off value for respiratory disturbance being used (1). Finally, 
assessment of the overall inflammatory status, as inferred from a subset of such biomarkers 
not only reliably reflects the improvements in systemic inflammation elicited by T&A 
treatment of OSA, but may also provide a relatively robust surrogate reporter of OSA 
resolution vs. the presence of residual OSA.
Before discussing the potential implications of our findings, we will initially focus on the 
individual inflammatory mediators that significantly changed after T&A. MMP-9 belongs to 
a large family of zinc-containing enzymes that degrade extracellular matrix (17), and plays 
important roles in obesity and attendant risk for cardiovascular and metabolic dysfunction 
(18, 19). Evidence for increased MMP-9 levels has been controversial in obese children, and 
may reflect genomic variances (20-22). However, studies in both adults and children have 
indicated increases in MMP-9 levels in the presence of OSA, with the corollary assumption 
that altered MMP-9 levels may reflect atherogenic risk in these patients (23-25). Our 
findings are in agreement with those of Kaditis et al who found significant increases in 
MMP-9 levels in c=obese children with moderate to severe OSA (25), and provide initial 
cause and effect insights as to the contribution of OSA to MMP-9 circulating levels in obese 
children, as delineated by the T&A-induced changes leading to effective OSA resolution, 
and also suggest the potential underlying cardiovascular risk traditionally associated with 
OSA-induced increases in MMP-9. MCP-1 is a central member of the C-C chemokine 
superfamily responsible for attracting mononuclear cells to inflammatory sites. MCP-1 
increases with obesity in children and lifestyle interventions reduce MCP-1 plasma levels 
(26-28). Furthermore, MCP-1 elevations have been reported in adult patients with OSA with 
reductions in MCP-1 levels being reported after continuous positive airway pressure (CPAP) 
treatment (29, 30). As in adults, effective treatment of OSA in the current obese pediatric 
cohort resulted in significant reductions in MCP-1 levels, further reinforcing the concept of 
reduced inflammatory state and metabolic and cardiovascular risk resulting from effective 
treatment of OSA (31). However, even though adiponectin reductions have been clearly 
identified in obese patients and associated to inflammatory burden as evidenced by increases 
in IL-6 and MCP-1 levels (32), here we found that OSA treatment elicited no changes in 
plasma adiponectin levels despite the decreases in MCP-1 in the total cohort. However, in 
the subset of children in whom OSA was effectively treated with T&A, significant increases 
in adiponectin emerged (Table 4). We should remark that our results herein were somewhat 
anticipated considering the previously reported significant, albeit inconsistent associations 
between plasma adipokines, namely leptin and adiponectin, and the severity of OSA 
(33-36). Notably, small yet significant reduction in leptin levels occurred in effectively 
treated children while increases in leptin emerged in those with residual OSA (Table 4; 37). 
Although we are unaware of any previous studies examining the effect of OSA treatment on 
PAI-1 levels in children, PAI-1 has been suggested as a reliable biomarker for metabolic 
syndrome (38), as well as a robust predictor of vascular complications in children (39). In 
adults with OSA, conflictive findings have been reported whereby improvements in PAI-1 
levels have been inconsistently found following treatment (40-44). Here, we confirm that 
obese children with OSA have not only increased plasma levels of PAI-1 (5), but that T&A, 
particularly when effectively normalizing the respiratory disturbance during sleep leads to 
significant reductions in PAI-1 levels, thereby suggesting previously reported inferences 
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between OSA and vascular dysfunction (45-48). Increased IL-6 concentrations have now 
been consistently reported in both adults and children with OSA, notwithstanding the 
attributable genetic variation that modulates such findings (49-51). Here, the usefulness of 
performing serial IL-6 measurements as a potential biomarker aiming to identify T&A 
outcomes in obese children with OSA was not confirmed. We should also remark that we 
have previously reported the increases in adropin levels that accompany effective treatment 
of OSA in a group of children with OSA, and the unique value of this biomarker in 
specifically identifying children with endothelial dysfunction (52). Thus, the improvements 
in circulating adropin concentrations after T&A would suggest the presence of underlying 
ameliorations in diffuse endothelial injury elicited by interactions between OSA and obesity 
(53).
The current study assessed T&A outcomes for the first time in a large obese pediatric cohort 
that was prospectively recruited from the community. As reported above, the changes in 
systemic inflammatory markers were selective, and also reflected the overall T&A outcomes 
as far as the magnitude of sleep-disordered breathing after surgery. Our study also 
emphasizes the relatively less favorable impact of T&A on an obese population with OSA, 
independently of the respiratory measure cut-off selected as evidence of resolution of OSA. 
The reduced likelihood for complete resolution of OSA after T&A has now been extensively 
noted in several retrospective studies, as well as in both non-randomized and randomized 
prospective trials (54-62). One possible explanation for such relatively unfavorable 
outcomes could reside in the propensity for accelerated weight gain that occurs after T&A in 
some obese children (63, 64), but such differences were not present in the present cohort.
In summary, this study provides conclusive evidence for the presence of elevations in 
selected systemic inflammatory markers among obese children with OSA, and 
improvements after T&A, particularly when the magnitude of respiratory disturbance 
expressed as AHI is below 5/hrTST after treatment. Further studies are needed to investigate 
the role of some of these markers as correlates of T&A outcomes, as well as their 
significance relative to OSA and obesity-associated end-organ morbidities. In this context, if 
future studies confirm the validity of these biomarkers in the identification of children with 
clinically significant residual OSA, their implementation into the clinical setting should pose 
no major technical problem and could potentially reduce the cost associated with routine 
post-T&A PSG in all obese children with OSA, as is currently recommended (1).
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Figure 1. 
Receiver operator curves using individual plasma metabolic or inflammatory markers 
defined cut-off values for prediction of residual OSA after T&A in obese children.
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Table 1
Antropometric measures in 100 obese children with OSA before and after adenotonsillectomy (T&A) and in 
24 children with OSA who did not return for follow-up after T&A.
Pre-T&A Post-T&A p value Pre-T&A
Lost to F/U
Age (years) 10.7 ± 2.4 11.4 ± 2.8 10.5± 2.8
Gender (Male / Female) 54/46 13/11
Height (m) 1.47 ± 0.14 1.53 ± 0.17 <0.01 1.49± 0.23
Weight (Kg) 63.2 ± 17.6 66.9 ± 20.1 <0.01 64.3±18.9
BMI 26.8 ± 4.1 27.7 ± 4.6 <0.05 26.9±5.3
BMI % 96.7 ± 0.6 98.1 ± 0.7 <0.05 96.8±0.8
BMI z score 1.78±0.23 1.83±0.29 <0.05 1.79±0.28
Neck Circumference (cm) 33.7 ± 3.8 34.3 ± 3.8 >0.05 33.9±4.2
Waist circumference /Hip circumference 0.92 ± 0.06 0.97 ± 0.07 >0.05 0.93±0.08
*
Data presented as Mean ± SD
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Table 2
Polysomnographic characteristics in 100 obese children before and following adenotonsillectomy (T&A) and 
in 24 children with OSA who did not return for follow-up after T&A.
Pre T&A Post T&A p value Pre-T&A
Lost to F/U
Time in Bed (min) 486.8 ± 45.2 482.1 ± 46.4 0.9 488.7±65.2
Total sleep time (min) 394.6 ± 67.2 392.5 ± 65.3 0.9 392.9±78.7
Sleep Efficiency % 79.1 ± 10.2 80.3 ± 12.4 0.9 78.9±14.7
Arousal Index (/hrTST) 17.5 ± 10.1 12.5 ± 8.1 <0.001† 17.8±14.2
AHI (hrTST) 17.1± 17.8 4.5± 5.3 <0.0001† 18.4±23.6
Respiratory Disturbance Index (/hrTST) 20.4 ± 18.9 7.2 ± 10.5 <0.001† 22.6±22.7
Obstructive RDI (/hrTST) 19.8 ± 21.3 4.1 ± 4.9 <0.001† 20.8±23.2
Baseline SpO2 (%) 98.3 ± 1.8 98.9 ± 1.3 0.2 98.3±2.1
Nadir SpO2 (%) 81.4 ± 9.5 88.2 ±6.2 0.0001† 80.9±11.2
Time SpO2 <90% 2.8 ± 3.3 1.1 ± 2.9 0.01† 2.9±3.7
Oxygen Desaturation Index (/hrTST) 7.1 ± 8.2 2.2 ± 5.7 0.001† 7.4±9.7
Peak End-Tidal CO2 (mmHg) 49.1 ± 7.1 46.2 ± 8.3 0.001† 49.0±8.2
Total Sleep time with End-Tidal CO2>50 mmHg (min) 36.7 ± 15.6 28.9 ± 17.7 0.003† 35.9±17.3
†Statistically significant difference
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Table 3
Plasma inflammatory markers before and after T&A in 100 obese children with OSA.
Pre T&A Post T&A p value
IL-6 (pg/ml) 9.2 ± 5.4
[2.1 – 18.3]
7.1 ± 4.7
[2.0 – 19.7] 0.0001
†
PAI-1 (ng/ml) 5.1 ± 1.7
[1.5 – 11.5]
3.7 ± 1.6
[0.5 – 5.8] 0.0001
†
MCP-1 (pg/ml) 50.6 ± 15.6
[24.7 – 115.8]
42.5 ± 17.7
[16.4 – 112.7] 0.003
†
MMP-9 (μg/ml) 1.08 ± 0.69
[0.18 – 5.01]
0.78 ± 0.42
[0.25 – 2.3] 0.0001
†
IL-18 (pg/ml) 222.2± 130.6
[96.5-654.3]
201.8± 132.2
[35.0-433.2] 0.005
†
Apelin C (ng/ml) 168.9± 75.5
[38.7-414.4]
147.6± 79.2
[7.23-422.4]
0.5
Adropin (ng/ml) 5.6± 3.8
[1.1-18.6]
7.5± 3.4
[3.0-16.0] 0.0001
†
Leptin (ng/ml) 21.9±6.3
[3.2-34.2]
20.8±7.1
[4.0-38.5]
0.2
Adiponectin (μg/ml) 39.7±17.8
[10.5-87.7]
41.5±15.9
[10.2-88.7]
0.2
Osteocrin (ng/ml) 19.0±22.0
[0.4-84.9]
23.1±22.4
[0.3-121.3]
0.06
*
Data presented as Mean ± SD [range]
†Statistically significant difference
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